ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
20 01 2022
Historique:
received: 13 12 2020
accepted: 26 09 2021
pubmed: 9 10 2021
medline: 8 3 2022
entrez: 8 10 2021
Statut: ppublish

Résumé

Mixed-phenotype acute leukemia is a rare subtype of leukemia in which both myeloid and lymphoid markers are co-expressed on the same malignant cells. The pathogenesis is largely unknown, and the treatment is challenging. We previously reported the specific association of the recurrent t(8;12)(q13;p13) chromosomal translocation that creates the ETV6-NCOA2 fusion with T/myeloid leukemias. Here we report that ETV6-NCOA2 initiates T/myeloid leukemia in preclinical models; ectopic expression of ETV6-NCOA2 in mouse bone marrow hematopoietic progenitors induced T/myeloid lymphoma accompanied by spontaneous Notch1-activating mutations. Similarly, cotransduction of human cord blood CD34+ progenitors with ETV6-NCOA2 and a nontransforming NOTCH1 mutant induced T/myeloid leukemia in immunodeficient mice; the immunophenotype and gene expression pattern were similar to those of patient-derived ETV6-NCOA2 leukemias. Mechanistically, we show that ETV6-NCOA2 forms a transcriptional complex with ETV6 and the histone acetyltransferase p300, leading to derepression of ETV6 target genes. The expression of ETV6-NCOA2 in human and mouse nonthymic hematopoietic progenitor cells induces transcriptional dysregulation, which activates a lymphoid program while failing to repress the expression of myeloid genes such as CSF1 and MEF2C. The ETV6-NCOA2 induced arrest at an early immature T-cell developmental stage. The additional acquisition of activating NOTCH1 mutations transforms the early immature ETV6-NCOA2 cells into T/myeloid leukemias. Here, we describe the first preclinical model to depict the initiation of T/myeloid leukemia by a specific somatic genetic aberration.

Identifiants

pubmed: 34624096
pii: S0006-4971(21)01711-0
doi: 10.1182/blood.2020010405
pmc: PMC9906988
doi:

Substances chimiques

NCOA2 protein, human 0
Nuclear Receptor Coactivator 2 0
Oncogene Proteins, Fusion 0
Proto-Oncogene Proteins c-ets 0
Repressor Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

399-412

Subventions

Organisme : NCI NIH HHS
ID : R35 CA210065
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 by The American Society of Hematology.

Références

Cancer Cell. 2004 Dec;6(6):587-96
pubmed: 15607963
Leuk Lymphoma. 2017 Dec;58(12):2895-2904
pubmed: 28482719
Semin Immunol. 2008 Aug;20(4):236-46
pubmed: 18768329
Nat Genet. 2013 Dec;45(12):1494-8
pubmed: 24141364
EMBO J. 2010 Jul 7;29(13):2147-60
pubmed: 20517297
Nat Genet. 2017 Aug;49(8):1274-1281
pubmed: 28671687
Br J Haematol. 2010 Apr;149(1):84-92
pubmed: 20085575
Nat Immunol. 2009 Mar;10(3):289-96
pubmed: 19169261
J Clin Invest. 2008 Sep;118(9):3181-94
pubmed: 18677410
Exp Hematol. 2016 Aug;44(8):740-4
pubmed: 27208809
Clin Cancer Res. 2008 Feb 15;14(4):977-83
pubmed: 18281529
J Immunol. 2014 May 1;192(9):4017-23
pubmed: 24748636
Nat Immunol. 2013 Jul;14(7):756-63
pubmed: 23708252
Leukemia. 2010 Oct;24(10):1785-8
pubmed: 20686503
Haematologica. 2014 Jan;99(1):94-102
pubmed: 23975177
Nat Rev Immunol. 2013 Jun;13(6):427-37
pubmed: 23665520
Nucleic Acids Res. 2015 Jul 1;43(W1):W57-64
pubmed: 25925574
Nat Immunol. 2019 Nov;20(11):1456-1468
pubmed: 31636466
Br J Haematol. 2018 May;181(3):392-394
pubmed: 28272805
J Biol Chem. 2006 Jun 23;281(25):17124-17133
pubmed: 16613851
Nature. 2018 Oct;562(7727):373-379
pubmed: 30209392
Cancer Cell. 2003 Mar;3(3):259-71
pubmed: 12676584
Genes Dev. 2000 May 15;14(10):1209-28
pubmed: 10817756
Semin Cancer Biol. 2005 Jun;15(3):162-74
pubmed: 15826831
Lancet Oncol. 2009 Feb;10(2):147-56
pubmed: 19147408
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Cell. 2018 Feb 8;172(4):869-880.e19
pubmed: 29398116
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Am J Hematol. 2018 Nov;93(11):1358-1367
pubmed: 30117174
Nat Commun. 2018 Jul 10;9(1):2670
pubmed: 29991687
Leuk Res. 2012 Aug;36(8):945-61
pubmed: 22578774
Immunol Cell Biol. 2011 Jan;89(1):16-26
pubmed: 20956988
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Blood. 2005 Jul 1;106(1):274-86
pubmed: 15774621
J Biol Chem. 1999 Oct 15;274(42):30132-8
pubmed: 10514502
Leuk Res. 1999 Oct;23(10):895-9
pubmed: 10573134
J Exp Med. 2011 Dec 19;208(13):2571-9
pubmed: 22162831
Nature. 2017 Oct 5;550(7674):128-132
pubmed: 28953875
Cancer Discov. 2021 Nov;11(11):2846-2867
pubmed: 34103329
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20100-5
pubmed: 19104054
Development. 2013 Mar;140(6):1207-19
pubmed: 23444353
Nat Protoc. 2013 Dec;8(12):2502-15
pubmed: 24263090
Oncogene. 2005 Jun 9;24(25):4129-37
pubmed: 15806161
Haematologica. 2012 Nov;97(11):1708-12
pubmed: 22581002
Leukemia. 2006 Mar;20(3):537-9
pubmed: 16424867
Int J Cancer. 1976 Oct 15;18(4):421-31
pubmed: 789258
Blood. 2013 Nov 7;122(19):3385-7
pubmed: 24203929
Cell Syst. 2019 Oct 23;9(4):321-337.e9
pubmed: 31629685
EMBO J. 2001 Aug 1;20(15):4173-82
pubmed: 11483520
Nat Med. 2010 May;16(5):580-5, 1p following 585
pubmed: 20418886
Mol Cell. 2016 Jan 7;61(1):170-80
pubmed: 26687680
Blood. 1998 May 1;91(9):3127-33
pubmed: 9558366
Mol Cancer. 2007 Aug 13;6:51
pubmed: 17697320
Nucleic Acids Res. 2012 Aug;40(15):e114
pubmed: 22718975
Cancer Cell. 2011 Apr 12;19(4):484-97
pubmed: 21481790
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Immunogenetics. 2012 Aug;64(8):591-604
pubmed: 22581009
J Clin Oncol. 2017 Mar 20;35(9):975-983
pubmed: 28297628
Semin Hematol. 2017 Apr;54(2):98-104
pubmed: 28637624
Genes Dev. 2015 Apr 15;29(8):832-48
pubmed: 25846797
Nature. 2012 Jan 11;481(7380):157-63
pubmed: 22237106
EMBO J. 1998 Jan 15;17(2):507-19
pubmed: 9430642

Auteurs

Hila Fishman (H)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cancer Research Center, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel.
Rina Zaizov Pediatric Hematology Oncology Division, Schneider Children's Medical Center of Israel, Petah Tikvah, Israel.

Shreyas Madiwale (S)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Rina Zaizov Pediatric Hematology Oncology Division, Schneider Children's Medical Center of Israel, Petah Tikvah, Israel.

Ifat Geron (I)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cancer Research Center, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel.
Rina Zaizov Pediatric Hematology Oncology Division, Schneider Children's Medical Center of Israel, Petah Tikvah, Israel.

Vase Bari (V)

Cancer and Blood Diseases Institute, Cincinnati Children's Hospital, Cincinnati, OH.

Wouter Van Loocke (W)

Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium.

Yael Kirschenbaum (Y)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cancer Research Center, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel.

Itamar Ganmore (I)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cancer Research Center, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel.

Eitan Kugler (E)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cancer Research Center, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel.
Rina Zaizov Pediatric Hematology Oncology Division, Schneider Children's Medical Center of Israel, Petah Tikvah, Israel.

Avigail Rein-Gil (A)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cancer Research Center, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel.
Rina Zaizov Pediatric Hematology Oncology Division, Schneider Children's Medical Center of Israel, Petah Tikvah, Israel.

Gilgi Friedlander (G)

The Mantoux Bioinformatics Institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel.

Ginette Schiby (G)

Institute for Pathology Laboratory, Hematology Institute, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel.

Yehudit Birger (Y)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cancer Research Center, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel.
Rina Zaizov Pediatric Hematology Oncology Division, Schneider Children's Medical Center of Israel, Petah Tikvah, Israel.

Sabine Strehl (S)

Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.

Jean Soulier (J)

Genomes and Cell Biology of Disease, Hôpital Saint-Louis, Paris, France.

Birgit Knoechel (B)

Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA.

Adolfo Ferrando (A)

Institute for Cancer Genetics, Columbia University, New York, NY.

Sharon Noy-Lotan (S)

Rina Zaizov Pediatric Hematology Oncology Division, Schneider Children's Medical Center of Israel, Petah Tikvah, Israel.

Arnon Nagler (A)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hematology Division Bone Marrow Transplants and Cord-Blood Bank, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel; and.

James C Mulloy (JC)

Cancer and Blood Diseases Institute, Cincinnati Children's Hospital, Cincinnati, OH.

Pieter Van Vlierberghe (P)

Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium.

Shai Izraeli (S)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cancer Research Center, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel.
Rina Zaizov Pediatric Hematology Oncology Division, Schneider Children's Medical Center of Israel, Petah Tikvah, Israel.
Department of System Biology, City of Hope, Duarte, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH